TxCell and Lonza entered into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation.
Today, CRISPR/Cas9 has emerged as the genome editing method of choice in research and biotechnology. Compared to other gene editing technologies, it is simpler to re-engineer, easier to use, and can target multiple sites.
Lonza Pharma & Biotech announced the investment in a new phase of development at their Portsmouth (New Hampshire, USA) site. The expansion will include mid-scale mammalian capacity and the addition of new cell-therapy suites.
On 24 April 2018, Lonza is hosting a free 60-minute webinar on the best practices for connecting and integrating devices and systems in QC and production, which I thought would be of interest to you and your readers.